Skip to main content
. 2018 Apr 30;7(3):248–256. doi: 10.1016/j.imr.2018.04.002

Table 2.

Patient Characteristics and Medication Use at Trial Entry

No. enrolled 119
No. completing 12 weeks follow up (Male/Female) 103 (60/43)
Median age years (range) 57 (28–78)
Mean weight kilograms (range) 81 (49–135)
Mean Body Mass Index (kg/m2) 30.3
Mean fasting glucose mg/dL (range) 211 (107–513)
Mean Hemoglobin A1c % (range) 9 (6–17)
Mean total cholesterol mg/dL (range) 212 (100–706)
Mean triglyceride mg/dL (range) 266 (151–1520)
Insulin use no. (% of total patients) 13 (12.6%)
Sulphonylurea use no. (% of total) 19 (18.4%)
Biguanide use no. (% of total) 44(42.7%)
Meglitinide uses no. (% of total) 2 (1.94%)
Combination oral hypoglycemic use no. (% of total) 25 (24.3%)
Antihypertensive medications % of total 38%
Anti-lipid medication (statins and fibrates) % of total 45%

mg/dL = milligrams per deciliter. kg/m2 = kilograms per square meter.